New beta blockers

Here are some new beta blockers that have been approved or are in development:

  1. Lixivaptan (Corlux): This is a novel beta blocker that is being developed by Corvidia Therapeutics for the treatment of hypertension and heart failure. It has shown promising results in clinical trials, including a significant reduction in blood pressure and improved cardiac function.
  2. Bucindolol (Bucindolol): This is a beta blocker that is being developed by Cardium Therapeutics for the treatment of heart failure. It has shown improved outcomes in patients with heart failure, including reduced hospitalizations and improved quality of life.
  3. Nebivolol (Bystolic): This is a beta blocker that is being developed by Forest Laboratories for the treatment of hypertension. It has shown improved blood pressure control and reduced cardiovascular events in clinical trials.
  4. Metoprolol succinate (Toprol-XL): This is a beta blocker that is being developed by AstraZeneca for the treatment of hypertension and heart failure. It has shown improved blood pressure control and reduced cardiovascular events in clinical trials.
  5. Carvedilol (Coreg): This is a beta blocker that is being developed by GlaxoSmithKline for the treatment of hypertension and heart failure. It has shown improved blood pressure control and reduced cardiovascular events in clinical trials.
  6. Propranolol (Inderal): This is a beta blocker that is being developed by Pfizer for the treatment of hypertension and anxiety disorders. It has shown improved blood pressure control and reduced symptoms of anxiety in clinical trials.
  7. Timolol (Blocadren): This is a beta blocker that is being developed by Allergan for the treatment of hypertension and glaucoma. It has shown improved blood pressure control and reduced intraocular pressure in clinical trials.
  8. Betaxolol (Kerlone): This is a beta blocker that is being developed by GlaxoSmithKline for the treatment of hypertension and glaucoma. It has shown improved blood pressure control and reduced intraocular pressure in clinical trials.
  9. Celiprolol (Celiprolol): This is a beta blocker that is being developed by Daiichi Sankyo for the treatment of hypertension and heart failure. It has shown improved blood pressure control and reduced cardiovascular events in clinical trials.
  10. Nebivolol (Bystolic): This is a beta blocker that is being developed by Forest Laboratories for the treatment of hypertension. It has shown improved blood pressure control and reduced cardiovascular events in clinical trials.

Please note that this is not an exhaustive list, and new beta blockers are being developed and approved all the time. Additionally, the availability and approval of these medications may vary depending on the country and region.